Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United…
Biotechnology
US, South San Francisco [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Harpoon Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2023 | -20.2400 | -1.490 | 31 | 36 | -67 | -4 | -65 | -33 | -71 | -36 | 18 | 54 |
| 2024 | - | -4.560 | - | 55 | - | -15 | - | -51 | - | -55 | - | 82 |
| 2025 | - | -2.790 | - | 18 | - | -9 | - | -17 | - | -18 | - | 28 |